| First Author | Li R | Year | 2015 |
| Journal | Diabetes | Volume | 64 |
| Issue | 2 | Pages | 529-40 |
| PubMed ID | 25332429 | Mgi Jnum | J:246077 |
| Mgi Id | MGI:5922896 | Doi | 10.2337/db13-1737 |
| Citation | Li R, et al. (2015) PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes 64(2):529-40 |
| abstractText | A breakdown in self-tolerance underlies autoimmune destruction of beta-cells and type 1 diabetes. A cure by restoring beta-cell mass is limited by the availability of transplantable beta-cells and the need for chronic immunosuppression. Evidence indicates that inhibiting costimulation through the PD-1/PD-L1 pathway is central to immune tolerance. We therefore tested whether induction of islet neogenesis in the liver, protected by PD-L1-driven tolerance, reverses diabetes in NOD mice. We demonstrated a robust induction of neo-islets in the liver of diabetic NOD mice by gene transfer of Neurogenin3, the islet-defining factor, along with betacellulin, an islet growth factor. These neo-islets expressed all the major pancreatic hormones and transcription factors. However, an enduring restoration of glucose-stimulated insulin secretion and euglycemia occurs only when tolerance is also induced by the targeted overexpression of PD-L1 in the neo-islets, which results in inhibition of proliferation and increased apoptosis of infiltrating CD4(+) T cells. Further analysis revealed an inhibition of cytokine production from lymphocytes isolated from the liver but not from the spleen of treated mice, indicating that treatment did not result in generalized immunosuppression. This treatment strategy leads to persistence of functional neo-islets that resist autoimmune destruction and consequently an enduring reversal of diabetes in NOD mice. |
